[ad_1]
Privately-held Italian drugmaker Chiesi announced that its new
center of excellence for the development and production of
biologic drugs, currently under construction, will be built in
Parma in the area of the production plant where the company is
headquartered.
Expected to open and be fully operational in 2024, the center
will specialize in the development and production of the active
ingredients of monoclonal antibodies (MAbs) that are produced
through…
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Try before you buy
• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
• Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
• Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
• Daily roundup of key events in pharma and biotech.
• Monthly in-depth briefings on Boardroom appointments and M&A news.
• Choose from a cost-effective annual package or a flexible monthly subscription.
[ad_2]
Source link